• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

克林沙星、曲伐沙星、奎奴普丁/达福普丁及其他抗菌药物对万古霉素敏感性降低的金黄色葡萄球菌分离株的活性。

Activity of clinafloxacin, trovafloxacin, quinupristin/dalfopristin, and other antimicrobial agents versus Staphylococcus aureus isolates with reduced susceptibility to vancomycin.

作者信息

Cohen M A, Huband M D

机构信息

Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan 48105-2495, USA.

出版信息

Diagn Microbiol Infect Dis. 1999 Jan;33(1):43-6. doi: 10.1016/s0732-8893(98)00121-7.

DOI:10.1016/s0732-8893(98)00121-7
PMID:9990475
Abstract

Isolations of Staphylococcus aureus strains with reduced susceptibility to vancomycin are now being reported worldwide. In testing here by broth microdilution according to NCCLS guidelines and applying vancomycin breakpoint criteria (susceptible at 4 micrograms/mL), two of three strains were susceptible (MICs at 4 micrograms/mL) rather than intermediate (MICs at 8 micrograms/mL) as previously reported by other laboratories. Clinafloxacin was more active (MICs/MBCs at 0.5 to 2 micrograms/mL) than ciprofloxacin, grepafloxacin, levofloxacin, ofloxacin, and sparfloxacin. Trovafloxacin, trimethoprim/sulfamethoxazole, and quinupristin/dalfopristin were the next most active agents, although quinupristin/dalfopristin was bactericidal against only two of these three strains. Amikacin, imipenem, oxacillin, and rifampin were less active.

摘要

目前全球都在报道对万古霉素敏感性降低的金黄色葡萄球菌菌株的分离情况。按照美国国家临床实验室标准委员会(NCCLS)指南通过肉汤微量稀释法进行检测,并应用万古霉素断点标准(4微克/毫升时敏感),在检测的三株菌株中,有两株是敏感的(最低抑菌浓度为4微克/毫升),而不是如其他实验室先前报道的为中介(最低抑菌浓度为8微克/毫升)。克林沙星比环丙沙星、格帕沙星、左氧氟沙星、氧氟沙星和司帕沙星更具活性(最低抑菌浓度/最低杀菌浓度为0.5至2微克/毫升)。曲伐沙星、甲氧苄啶/磺胺甲恶唑和奎奴普丁/达福普汀是其次活性最高的药物,不过奎奴普丁/达福普汀对这三株菌株中只有两株具有杀菌作用。阿米卡星、亚胺培南、苯唑西林和利福平活性较低。

相似文献

1
Activity of clinafloxacin, trovafloxacin, quinupristin/dalfopristin, and other antimicrobial agents versus Staphylococcus aureus isolates with reduced susceptibility to vancomycin.克林沙星、曲伐沙星、奎奴普丁/达福普丁及其他抗菌药物对万古霉素敏感性降低的金黄色葡萄球菌分离株的活性。
Diagn Microbiol Infect Dis. 1999 Jan;33(1):43-6. doi: 10.1016/s0732-8893(98)00121-7.
2
Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains.克林沙星、格帕沙星、左氧氟沙星、莫西沙星、氧氟沙星、司帕沙星、曲伐沙星以及非喹诺酮类药物利奈唑胺、奎奴普丁-达福普汀、庆大霉素和万古霉素对耐环丙沙星和环丙沙星敏感金黄色葡萄球菌临床分离株的比较活性。
Antimicrob Agents Chemother. 1999 Feb;43(2):421-3. doi: 10.1128/AAC.43.2.421.
3
Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria.RP59500(奎奴普丁/达福普汀)、CL 329,998、CL 331,002、曲伐沙星、克林沙星、替考拉宁和万古霉素对革兰氏阳性菌的体外活性比较
J Antimicrob Chemother. 1997 Mar;39(3):405-9. doi: 10.1093/jac/39.3.405.
4
In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis.两种新型恶唑烷酮类药物(U100592和U100766)、一种新型氟喹诺酮类药物(曲伐沙星)以及达福普汀-奎奴普汀对金黄色葡萄球菌和表皮葡萄球菌的体外活性。
Antimicrob Agents Chemother. 1996 Oct;40(10):2428-30. doi: 10.1128/AAC.40.10.2428.
5
Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agents.新型抗菌药物(曲伐沙星、莫西沙星、三氟沙星和奎奴普丁-达福普汀)对脆弱拟杆菌属的活性:与其他14种药物活性的比较。
Antimicrob Agents Chemother. 1999 Sep;43(9):2320-2. doi: 10.1128/AAC.43.9.2320.
6
[Vancomycin-resistant enterococci: in vitro activity of quinupristin / dalfoprostin (RP 59500)].[耐万古霉素肠球菌:奎奴普丁/达福普汀(RP 59500)的体外活性]
Enferm Infecc Microbiol Clin. 1999 Aug-Sep;17(7):335-9.
7
Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.对从美国和加拿大200个医疗中心收集的28000多株近期临床分离菌进行了奎奴普丁-达福普汀(RP 59500,Synercid)的抗菌活性测试。
Diagn Microbiol Infect Dis. 1998 Jul;31(3):437-51. doi: 10.1016/s0732-8893(98)80002-3.
8
Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan.台湾革兰氏阳性菌对奎奴普丁-达福普汀的耐药性
Antimicrob Agents Chemother. 2000 Dec;44(12):3374-80. doi: 10.1128/AAC.44.12.3374-3380.2000.
9
In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.达托霉素、利奈唑胺和奎奴普丁-达福普汀对包括万古霉素中介金黄色葡萄球菌和万古霉素耐药粪肠球菌在内的葡萄球菌和肠球菌挑战组的体外活性。
Microb Drug Resist. 2003 Winter;9(4):389-93. doi: 10.1089/107662903322762833.
10
In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium.奎奴普丁/达福普汀及新型喹诺酮类药物与庆大霉素联合应用对粪肠球菌和屎肠球菌耐药菌株的体外活性
Eur J Clin Microbiol Infect Dis. 1998 Sep;17(9):657-61. doi: 10.1007/BF01708351.

引用本文的文献

1
Nasal Carriage and Autoimmune Diseases: From Pathogenic Mechanisms to Disease Susceptibility and Phenotype.鼻腔携带与自身免疫性疾病:从发病机制到疾病易感性和表型。
Int J Mol Sci. 2019 Nov 11;20(22):5624. doi: 10.3390/ijms20225624.
2
An efficient Bi(NO3)3 x 5H2O catalyzed multi component one-pot synthesis of novel naphthyridines.一种高效的硝酸铋(Bi(NO₃)₃·5H₂O)催化多组分一锅法合成新型萘啶。
Mol Divers. 2008 May;12(2):139-42. doi: 10.1007/s11030-008-9081-0. Epub 2008 Jun 28.
3
Quinupristin/dalfopristin: the first available macrolide-lincosamide-streptogramin antibiotic.
奎奴普丁/达福普汀:第一种可获得的大环内酯-林可酰胺-链阳菌素类抗生素。
Proc (Bayl Univ Med Cent). 2000 Jan;13(1):83-6. doi: 10.1080/08998280.2000.11927646.
4
The use of antimicrobial peptides in ophthalmology: an experimental study in corneal preservation and the management of bacterial keratitis.抗菌肽在眼科的应用:角膜保存及细菌性角膜炎治疗的实验研究
Trans Am Ophthalmol Soc. 2002;100:243-71.
5
Drug interactions with clinafloxacin.克林沙星的药物相互作用。
Antimicrob Agents Chemother. 2001 Sep;45(9):2543-52. doi: 10.1128/AAC.45.9.2543-2552.2001.
6
Clinafloxacin pharmacokinetics in subjects with various degrees of renal function.不同程度肾功能受试者的克林沙星药代动力学
Antimicrob Agents Chemother. 2001 Sep;45(9):2536-42. doi: 10.1128/AAC.45.9.2536-2542.2001.
7
Pharmacokinetics of clinafloxacin after single and multiple doses.克林沙星单剂量和多剂量给药后的药代动力学
Antimicrob Agents Chemother. 2001 Sep;45(9):2529-35. doi: 10.1128/AAC.45.9.2529-2535.2001.
8
Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections.克林沙星与哌拉西林-他唑巴坦治疗重症皮肤及软组织感染患者的疗效比较
Antimicrob Agents Chemother. 2001 Feb;45(2):525-31. doi: 10.1128/AAC.45.2.525-531.2001.
9
Staphylococcus aureus Endocarditis in the 21st Century.21世纪的金黄色葡萄球菌性心内膜炎
Curr Infect Dis Rep. 2000 Aug;2(4):279-280. doi: 10.1007/s11908-000-0004-1.
10
Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.奎奴普丁/达福普汀:用于治疗严重革兰氏阳性菌感染的综述
Drugs. 1999 Dec;58(6):1061-97. doi: 10.2165/00003495-199958060-00008.